<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: For recurrent or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, a combination of leucovorin and fluorouracil with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX)is a standard first-line regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Although various FOLFOX regimens are widely used, the <z:hpo ids='HP_0001875'>neutropenia</z:hpo> caused by FOLFOX is often problematic </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to evaluate the clinical significance of bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> for recurrent or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> treated with FOLFOX+bevacizumab therapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Thirty-nine patients who had metastatic lesions from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> treated with FOLFOX+Bevacizumab at the Osaka Rosai Hospitalfrom January 2008 to December 2009 were included </plain></SENT>
<SENT sid="4" pm="."><plain>This study compared mFOLFOX6+Bevacizumab(mF6+BV)with mFOLFOX7+Bevacizumab( mF7+BV)to assess the clinical significance of bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Grade 3/4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> was significantly less in mF7+BV(58 </plain></SENT>
<SENT sid="6" pm="."><plain>8%: median 12 courses)than in mF6+BV(22 </plain></SENT>
<SENT sid="7" pm="."><plain>7%: median 11 courses)(P=0 </plain></SENT>
<SENT sid="8" pm="."><plain>02) </plain></SENT>
<SENT sid="9" pm="."><plain>Response rates were 52 </plain></SENT>
<SENT sid="10" pm="."><plain>9%in mF6+BV and 54 </plain></SENT>
<SENT sid="11" pm="."><plain>5%in mF7+BV(P=N </plain></SENT>
<SENT sid="12" pm="."><plain>S.) </plain></SENT>
<SENT sid="13" pm="."><plain>Relative dose intensities(RDI)during the first four courses of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> were 89% in mF6+BV and 94 </plain></SENT>
<SENT sid="14" pm="."><plain>6% in mF7+BV, respectively(P=N </plain></SENT>
<SENT sid="15" pm="."><plain>S.) </plain></SENT>
<SENT sid="16" pm="."><plain>Completion rates were 52 </plain></SENT>
<SENT sid="17" pm="."><plain>9% in mF6 +BV and 68 </plain></SENT>
<SENT sid="18" pm="."><plain>2% in mF7+BV, respectively(P=N </plain></SENT>
<SENT sid="19" pm="."><plain>S.) </plain></SENT>
<SENT sid="20" pm="."><plain>The main factors in RDI and completion rate decrease were hematologic toxicity </plain></SENT>
<SENT sid="21" pm="."><plain>The median PFS was 12 </plain></SENT>
<SENT sid="22" pm="."><plain>5 months in mF6+BV compared with 14 </plain></SENT>
<SENT sid="23" pm="."><plain>8 months in mF7+BV(P=0 </plain></SENT>
<SENT sid="24" pm="."><plain>91) </plain></SENT>
<SENT sid="25" pm="."><plain>CONCLUSIONS: The mFOLFOX7+BV regimen seems beneficialas first-line therapy in recurrent or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, demonstrating a decreased toxicity with an acceptable response rate and PFS </plain></SENT>
<SENT sid="26" pm="."><plain>Bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> may be unnecessary in a FOLFOX regimen </plain></SENT>
<SENT sid="27" pm="."><plain>Further study is needed to fully evaluate bolus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> </plain></SENT>
</text></document>